Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?

Ken J Harvey, Thomas A Faunce, Buddhima Lokuge and Peter Drahos
Med J Aust 2004; 181 (5): . || doi: 10.5694/j.1326-5377.2004.tb06264.x
Published online: 6 September 2004

In January 2003, the Pharmaceutical Research and Manufacturers of America lobbied the US negotiators for the Free Trade Agreement with Australia (AUSFTA) to seek a commitment from the Australian government to “refrain from trade distorting, abusive, or discriminatory price controls” in relation to the operation of its Pharmaceutical Benefits Scheme (PBS).1 In October 2003, President George Bush allegedly told Prime Minister John Howard that raising Australian prices for pharmaceuticals manufactured in the United States was important for ensuring that consumers in all countries, not just US consumers, paid for the high research and development (R&D) costs.2 AUSFTA was signed by both governments in May 2004. If we presume at least some of this rhetoric influenced the provisions of AUSFTA, what implications will these provisions have for our PBS?

  • 1 La Trobe University, Bundoora, VIC.
  • 2 Australian National University, Acton, ACT.


Competing interests:

None identified.

  • 1. Pharmaceutical Research and Manufacturers of America. National Trade Estimate Report on Foreign Trade Barriers (NTE) 2004. PHRMA, 2003. Available at: (accessed Jul 2004).
  • 2. Colebatch T. Bush wants end to medicine subsidies. The Age (Melbourne) 2003; 24 Oct: 5.
  • 3. Productivity Commission. International pharmaceutical price differences: research report. Melbourne, July 2001. Available at: (accessed Jul 2004).
  • 4. Harvey K, Murray M. Medicinal drug policy. In: Gardner H, editor. The politics of health, 2nd edition. Melbourne: Churchill Livingstone, 1995: 238-283.
  • 5. Department of Industry, Tourism and Resources. Pharmaceutical Industry Investment Program. 2004. Available at: (accessed Jul 2004).
  • 6. Families USA Foundation. Profiting from pain: where prescription drug dollars go. Washington, DC: Families USA, 2002. (Publication No. 02-105.) Available at: (accessed Jul 2004).
  • 7. Pear R. Drug companies increase spending on efforts to lobby Congress and governments. New York Times 2003; 1 June. Available at: (accessed Jul 2004).
  • 8. Public citizen. The other drug war 2003: drug companies deploy an army of 675 lobbyists to protect profits. Congress Watch, June 2003. Available at: (accessed Jul 2004).
  • 9. Panetta R. Review of PBS drug recommendatory decisions. Aust J Administrative Law 2003; 10: 146.
  • 10. Vaile M. Free Trade Agreement with the United States. Media Release, 8 February, MVT08/2004. Available at: (accessed Jul 2004).
  • 11. Hearing of the US Senate Finance Committee, Subcommittee on healthcare and international trade, 2004. Chaired by Senator Charles Grassley (R-IA). Testimony of Deputy U.S. Trade Representative Josette Sheeran Shiner, April 27, 2004. Available at: (accessed Jul 2004).
  • 12. Australian Government Department of Foreign Affairs and Trade. Australia-United States Free Trade Agreement. 2004. Full text, reports, fact sheets. Available at: (accessed Jul 2004).
  • 13. World Trade Organization. Doha Declaration on the TRIPS Agreement and Public Health. WT/MIN/(01)/Dec/2. Geneva: WTO, 2001.
  • 14. Is GSK guilty of fraud [editorial]? Lancet 2004; 363: 1919.
  • 15. Herxheimer A. Open access to industry's clinically relevant data: Urgently needed, but when will we get it, and in what form [editorial]? BMJ 2004; 329: 64-65. Available at:" (accessed Jul 2004).
  • 16. Mintzes B, Barer ML, Kazanjian A, et al. An assessment of the health system impacts of direct-to-consumer advertising of prescription medicines (DTCA). Vancouver, BC: Centre for Health Services and Policy Research, University of British Columbia, HPRU 02:1D February 2002. Available at: (accessed Jul 2004).
  • 17. Parliament of Australia, Senate Select Committee on the Free Trade Agreement between Australia and the United States of America. Interim report. Submissions and public hearing transcripts. 2004. Available at: (accessed Jul 2004).
  • 18. Lokuge B, Faunce TA, Denniss R. A backdoor to higher medicine prices? Intellectual property and the Australia-US Free Trade Agreement. Canberra: The Australia Institute, 2003.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.